History

Pacific Edge was formed in February 2001 with the goal of developing simple-to-use, non-invasive, highly accurate diagnostic and prognostic tools for cancer. As a result of a successful research and product development programme, Pacific Edge currently has a pipeline of products for the early detection, and/or management of targeted cancers.

Milestones to Date

September 2006	Pacific Edge Biotechnology Licenses Multigene Colorectal Cancer Diagnostics for European Market
August 2005	$NZ 2.5 million of new capital raised through Rights Issue to existing shareholders.
May 2005	Technology for Business Growth grant of over $1 million awarded for development of gastric cancer tool.
May 2004	Heads of Agreement signed with large Japanese pharmaceutical company.
December 2003	Formal negotiations initiated with major Japanese pharmaceutical companies to co-develop and commercialise gastric and bladder cancer markers.
July 2003	Comprehensive patent application for potential gastric cancer diagnostic markers filed in the United States.
February 2003	Completion of IPO.
February 2002	Pacific Edge Biotechnology lists on the NZ Stock Exchange.
January 2002	PEB fully staffed with 10 FTEs. World Class Scientific Advisory Board established.
August 2001	PEB established with NZ Seed Fund as its cornerstone shareholder and initial capital raising completed.
February 2001	PEB incorporated as a company.
February 2001	Intellectual Property identified and agreed to be acquired from the University of Otago.